Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Edge-to-Edge Tricuspid Valve Repair 3-Year Follow Up

Tricuspid regurgitation (TR) is associated to fatigue and peripheral edema, and medical treatment with diuretics has a limited impact. Tricuspid valve surgery is complex and entails 8 to 10% mortality. 

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

Edge-to-edge repair with TriClip has been shown beneficial in many studies, even though mainly short term. To date, we still lack data on mid and long term follow-up. 

The TRILUMINATE included 98 patients with moderate or severe symptomatic TR at high surgical risk, with no left sided heart failure or pulmonary disease with severe pulmonary hypertension. 

Patient mean age was 77, 66 were women. Mean EuroSCORE was 8.3. All patients were in functional class III-IV and presented atrial fibrillation (92%), kidney function deterioration (42%), diabetes (24%), prior mitral valve intervention (31%), and 14 had a pacemaker, AIC or CRT devices.

The most frequent TR was torrential, followed by severe, massive and, less frequently, moderate. Right ventricular ejection fraction was 36%, end diastolic diameter was 53 mm and vena cava diameter 23 mm.

Read also: Should We Withdraw Anticoagulation Before TAVR?

At three-year follow-up, there was sustained TR reduction in 79% of patients, as well as significant reduction of the contracted vein, effective regurgitant orifice and regurgitation volume. There was also improved functional class and quality of life, with reduced re-hospitalization rate after implantation. 

All-cause mortality at 3 years was 25%. There were 10 cases of bleeding, 4 of stroke, 1 of new liver failure, and 2 in need for pacemaker. 

Conclusion

The TRILUMINATE has shown edge-to-edge repair with TriClip is safe and effective, has sustained benefits for symptomatic patients with moderate to severe tricuspid valve failure, according to the available data

Original Title: Percutaneous Edge-to-Edge Repair for Tricuspid Regurgitation 3-Year Outcomes From the TRILUMINATE Study.

Reference: Georg Nickenig, et al. J Am Coll Cardiol Intv 2024 Artircle in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...